Basic information
- Standard SMILES
CC1=C(C)C(=O)C(C(CCCCCC(=O)O)c2ccccc2)=C(C)C1=O- InChIKey
ZBVKEHDGYSLCCC-UHFFFAOYSA-N- Molecular formula
- C22H26O4
- Average molar mass
- 354.4 g/mol
- Monoisotopic mass
- 354.18310931
Overview
Seratrodast is an organic molecular entity.
Names & identifiers
- Preferred name
- Seratrodast
- IUPAC
- 7-phenyl-7-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)heptanoic acid
- English name
- Seratrodast
- Molecular formula
- C22H26O4
- Molecular weight
- 354.44
Names & synonyms
Show more names
Database identifiers
- CAS
112665-43-7- PubChem CID
- 2449
- DTXSID
DTXSID4021397- ChEMBL
CHEMBL70972- ChEBI
CHEBI:32126- UNII
- 4U58JM421N
- EC Number
- 692-169-8
- Nikkaji
- J1.633.058B
Properties
Computed structural properties
- XLogP
- 4.4
- Topological polar surface area
- 71.4 Ų
- Hydrogen bond donors
- 1
- Hydrogen bond acceptors
- 4
- Rotatable bonds
- 8
- Heavy atoms
- 26
- Formal charge
- 0
- Complexity
- 633
Physicochemical properties
- Melting point
- 118 · 118-120°C
- Boiling point
- 522.3 · 522.3±49.0 °C(Predicted)
- Density
- 1.14 · 1.140±0.06 g/cm3(Predicted)
- storage temp.
- -20 °C · Sealed in dry,Store in freezer, under -20°C
- solubility
- Chloroform (Slightly), Methanol (Slightly)
- pka
- 4.76 · 4.76±0.10(Predicted)
- form
- Yellow-orange solid.
- color
- Pale Orange to Yellow
- Merck
- 14 · 14,8459
- InChI
- InChI=1S/C22H26O4/c1-14-15(2)22(26)20(16(3)21(14)25)18(17-10-6-4-7-11-17)12-8-5-9-13-19(23)24/h4,6-7,10-11,18H,5,8-9,12-13H2,1-3H3,(H,23,24)
- InChIKey
- ZBVKEHDGYSLCCC-UHFFFAOYSA-N
- SMILES
- C1(C)C(=O)C(C)=C(C(C2=CC=CC=C2)CCCCCC(=O)O)C(=O)C=1C
- CAS DataBase Reference
- 112665 · 112665-43-7(CAS DataBase Reference)
- FDA UNII
- 4 U58JM421N · 4U58JM421N
- ATC code
- 3 DX06 · R03DX06
- UNSPSC Code
- 51111800 · 51111800
- NACRES
- 77 · NA.77
- Symbol(GHS)
- 8 · GHS08
- Signal word
- Warning
- Hazard statements
- 361 · H361
- Precautionary statements
- 201 · P201-P202-P280-P308+P313-P405-P501
- WGK Germany
- 3 · WGK 3
- RTECS
- 1600050 · DA1600050
- HS Code
- 2918.3 · 2918.30.3000
- Storage Class
- 11 · 11 - Combustible Solids
- Hazard Classifications
- 2 · Repr. 2
Safety & regulation
GHS classification
GHS Classification
Warning
H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
P203, P280, P318, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 2 reports by companies from 1 notifications to the ECHA C&L Inventory.
Hazard information
Safety data
- wgk
- WGK 3
- rtecs
- DA1600050
- hs_code
- 2918.30.3000
- Signal word
- Warning
- Symbol(GHS)
- GHS08
- Storage Class
- 11 - Combustible Solids
- Hazard statements
- H361
- Hazard Classifications
- Repr. 2
- Precautionary statements
- P201-P202-P280-P308+P313-P405-P501
Chemistry & industry
Pharmacology
ATC Code
R - Respiratory system
QR - Respiratory system
MeSH Pharmacological Classification
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.
Compounds that inhibit the action of prostaglandins.
Drugs that are used to treat asthma.
Applications
DescriptionSeratrodast, a novel benzoquinone derivative, is the first thromboxane A2 (TxA2) receptor antagonist to reach the market. It is orally active for the treatment of bronchospastic disorders such as asthma. TxA2, a metabolite of the arachidonate cascade, is involved in several cardiovascular and respiratory diseases through its potent biological effects on platelet aggregation and constriction of vascular and respiratory smooth muscles. Seratrodast potently inhibits platelet aggregation and bronchoconstriction induced by a TxA2 mimic and by a variety of spasmogenic prostanoids including PGF2α, PGD2 and 9α,11β-PGF2. Seratrodast shows excellent efficacy in asthma and has been reported to be potentially useful in hyper-responsive disorder. The R-(+)- seratrodast was reported to be the active isomer.
UsesThromboxane A2-receptor antagonist. Antiasthmatic.
Usesantibacterial
Upstream & downstream products
Upstream raw materials
Suppliers50 total
Additional notes
DefinitionChEBI: Seratrodast is an organic molecular entity.
Related reactions
Linked notes
Loading…